Sesen Bio Inc (SESN) Stock
SESN is no longer traded. Sesen Bio was delisted from the Nasdaq in March 2023.
Prices on this page are historical; the last trade was March 7, 2023 at $0.63.
Sesen Bio stock price history
SESN final trading statistics
- Final close
- $0.63
- Final trading day
- Mar 7, 2023
- Market cap at delisting
- $127.96M
- Shares outstanding
- 203.49M
- Final 52-week range
- $0.36 – $0.96
- Avg. volume (final 3 mo.)
- 1,215,414
- All-time high (split-adj.)
- $5908.70 · Feb 2014
- All-time low (split-adj.)
- $0.58 · Mar 2023
- Return since IPO
- -100.0%
- Beta
- 0.83
- Book value / share
- $0.78
- Price / book
- 0.81
Sesen Bio annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $40.00M | -$19.9M | -$2.00 |
| FY2021 | $26.54M | -$336.0K | -$2.00 |
| FY2020 | $11.24M | -$22.4M | -$0.23 |
| FY2019 | $0.00 | -$107.5M | -$1.20 |
| FY2018 | $0.00 | -$33.7M | -$1.57 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Sesen Bio Inc
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Sesen Bio stock FAQ
What happened to Sesen Bio stock?
Sesen Bio stock was delisted from the Nasdaq. Its final close was $0.63 on March 7, 2023.
Is SESN stock still trading?
No. SESN was delisted from the Nasdaq in March 2023 and no longer trades on a U.S. exchange.
What was the last price of SESN stock?
SESN closed at $0.63 on its final trading day, March 7, 2023, for a market value of about $127.96M.
What were Sesen Bio's revenue and earnings in its last full fiscal year?
Sesen Bio reported revenue of $40.00M and net income of -$19.9M in fiscal 2022, its last full year as a public company.
When did Sesen Bio go public?
Sesen Bio Inc stock began trading on February 6, 2014.